Publication:
E2F1-induced upregulation of TROAP contributes to endometrial cancer progression

Thumbnail Image
Files
Wang-40-935-946-2025.pdf(8.33 MB)
Date
2025
relationships.isAuthorOfPublication
relationships.isSecondaryAuthorOf
relationships.isDirectorOf
Authors
Wang, Shanshan ; Sun, Yidan ; Guo, Minjing ; Zhu, Ping ; Xin, Beibei
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia, Departamento de Biologia Celular e Histiologia
publication.page.editor
publication.page.department
DOI
https://doi.org/10.14670/HH-18-834
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Purpose. To investigate the role of Trophinin-associated protein (TROAP) in endometrial cancer (EC) progression and elucidate how the transcription factor E2F transcription factor 1 (E2F1) modulates EC by upregulating TROAP expression. Methods. TROAP expression in EC tissues and cell lines was analyzed using bioinformatics databases, quantitative real-time polymerase chain reaction (qRT-PCR), western blot, and immunohistochemistry. TROAP was knocked down in EC cells to assess its effects on proliferation, migration, invasion, and glycolysis. Potential transcription factors regulating TROAP were identified, and the relationship between E2F1 and TROAP gene regulation was examined using dual luciferase assay. In vivo tumor growth was evaluated using a mouse xenograft model. Results. TROAP was overexpressed in EC tissues and cell lines compared with normal controls. High TROAP expression correlated with poor differentiation, advanced stage, lymph node metastasis, and worse overall survival in EC patients. Knockdown of TROAP inhibited the proliferation, migration, invasion, and glycolytic capacity of EC cells. E2F1 was identified as a transcriptional activator of TROAP. E2F1 over-expression enhanced TROAP expression and promoted EC cell proliferation, migration, and glycolysis in a TROAP-dependent manner. TROAP knockdown suppressed tumor growth in vivo. Conclusion. TROAP is transcriptionally activated by E2F1 and promotes EC progression by enhancing cell proliferation, metastasis, and glycolysis. The E2F1-TROAP axis may serve as a potential therapeutic target for EC treatment.
publication.page.subject
Endometrial cancer , Transcription factor , E2F1 , TROAP , Pathogenesis
Citation
Histology and Histopathology Vol. 40, nº06 (2025)
URI
http://hdl.handle.net/10201/154521
item.page.embargo
Collections
Histology and histopathology Vol.40, nº6 (2025)
Ir a Estadísticas